为解决 NDMM 患者高风险难以精准识别及现有风险分层工具不足的问题，梅奥诊所研究人员开展 S 期浆细胞比例对 NDMM 预后影响的研究。结果显示 S 期≥2% 是独立预后指标。该研究为精准治疗提供依据，值得科研读者一读。

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into ...

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients ...

Panelists discuss how to manage an aggressive case of early posttransplant progression in a young woman with functionally ...

Researchers sought to identify prognostic factors for survival in patients with newly diagnosed multiple myeloma.

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

Antengene’s Xpovio approved for reimbursement in Taiwan to treat adult patients with relapsed/refractory multiple myeloma: Shanghai Friday, February 14, 2025, 16:00 Hrs [IST] An ...

Hong Kong Department of Health accepts IASO Bio’s NDA for equecabtagene autoleucel to treat r/r multiple myeloma: Shanghai, Nanjing Monday, February 17, 2025, 17:00 Hrs [IST] IA ...

Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Bio, stated: ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...